Long term outcome data from the EORTC 75111-10114 ETF/BCG randomized phase II study: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer, followed by T-DM1 after progression.
- Resource Type
- Article
- Source
- Breast; Aug2022, Vol. 64, p100-111, 12p
- Subject
HER2 positive breast cancer METASTATIC breast cancer OLDER patients TRASTUZUMAB TUBERCULIN test OLDER people INTRAVESICAL administration - Language
- ISSN
- 09609776